Glucarpidase

DRUG10 trials

Conditions

Acute Kidney InjuryAcute Lymphoblastic Leukemia (ALL)Central Nervous System LymphomaChemotherapeutic Agent ToxicityDrug ToxicityLymphomaMucositisNeurotoxicity

Early Phase 1

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Active, not recruitingNCT03684980

Memorial Sloan Kettering Cancer CenterCentral Nervous System Lymphoma

Start: 2018-11-14End: 2027-11-01Updated: 2026-03-18

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Active, not recruitingNCT03960177

OHSU Knight Cancer InstituteOsteosarcoma

Start: 2019-03-27End: 2026-12-31Updated: 2026-01-07

Phase 1

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

CompletedNCT00727831

University College, LondonChemotherapeutic Agent Toxicity, Lymphoma, Mucositis +1

Start: 2008-07-31End: 2011-07-31Updated: 2014-01-27

Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma

NCT05135858

Assistance Publique - Hôpitaux de ParisPrimary Central Nervous System Lymphoma

Start: 2022-09-15End: 2025-07-31Target: 18Updated: 2022-10-25

Phase 2

High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

TerminatedNCT00634322

BTG International Inc.Osteosarcoma

Start: 2008-10-31End: 2009-04-30Updated: 2014-09-15

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

TerminatedNCT02022358

University College, LondonOsteosarcoma, Spindle Cell Sarcoma of Bone

Start: 2007-07-31End: 2015-06-30Updated: 2015-06-04

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

SuspendedNCT04668768

Fox Chase Cancer CenterLymphoma

Start: 2021-04-16End: 2025-04-30Updated: 2024-03-22

Phase 3

Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL

CompletedNCT01305655

Nordic Society for Pediatric Hematology and OncologyAcute Lymphoblastic Leukemia (ALL)

Start: 2008-07-31End: 2014-12-31Updated: 2018-09-28

Unknown Phase

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

CompletedNCT00018967

National Cancer Institute (NCI)Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific

Start: 1993-11-30Target: 10Updated: 2015-04-30

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

NCT05899751

Protherics Medicines Development LimitedAcute Kidney Injury, Drug Toxicity

Start: 2022-04-01End: 2024-12-31Target: 1000Updated: 2024-05-10

Related Papers

First results of the methoglu Trial, a phase 1 Trial from the LOC network evaluating the reduction of the time interval between methotrexate perfusions combined with glucarpidase in relapsed primary CNS lymphomas

Blood2025-11-03

CTNI-56. PLANNED GLUCARPIDASE FOR CNS LYMPHOMA PATIENTS AT HIGH RISK OF METHOTREXATE (MTX) TOXICITY

Neuro-Oncology2025-11-01

Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma

JCO Oncology Practice2024-06-252 citations

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC

HemaSphere2022-06-01

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.

2022-01-139 citations

Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.

2016-12-1438 citations